Aptose Biosciences Inc. (NASDAQ:APTO – Get Free Report) (TSE:APS) saw a large increase in short interest in February. As of February 28th, there was short interest totalling 122,600 shares, an increase of 63.7% from the February 13th total of 74,900 shares. Currently, 6.1% of the company’s stock are short sold. Based on an average daily trading volume, of 395,100 shares, the days-to-cover ratio is presently 0.3 days.
Aptose Biosciences Price Performance
NASDAQ APTO opened at $3.69 on Monday. Aptose Biosciences has a fifty-two week low of $2.39 and a fifty-two week high of $51.61. The stock’s 50-day moving average is $5.13 and its two-hundred day moving average is $8.04. The firm has a market cap of $7.90 million, a P/E ratio of -1.24 and a beta of 1.14.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price target on shares of Aptose Biosciences in a research note on Wednesday, February 12th. StockNews.com started coverage on Aptose Biosciences in a research report on Wednesday, March 5th. They issued a “sell” rating on the stock. Finally, Alliance Global Partners raised Aptose Biosciences to a “strong-buy” rating in a research note on Thursday, February 27th. One analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Aptose Biosciences currently has an average rating of “Moderate Buy” and an average target price of $130.00.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp grew its position in Aptose Biosciences Inc. (NASDAQ:APTO – Free Report) (TSE:APS) by 71.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the quarter. Sigma Planning Corp owned approximately 2.22% of Aptose Biosciences worth $165,000 as of its most recent SEC filing. 26.62% of the stock is currently owned by institutional investors.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
See Also
- Five stocks we like better than Aptose Biosciences
- How to Use High Beta Stocks to Maximize Your Investing Profits
- How to Build the Ultimate Everything ETF Portfolio
- Why Invest in High-Yield Dividend Stocks?
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Why Invest in 5G? How to Invest in 5G Stocks
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.